Equillium reports interim itolizumab data in LN: 50% CR at week 28, 67% >80% UPCR reduction

Equillium, Inc.

Baseline mean UPCR 5.8 g/g; 13 subjects enrolled, 11 reached week 12, 6 reached week 28/EOS.
At week 28: 3/6 (50%) achieved complete response (UPCR <0.7 g/g); 2/6 (33%) partial response.
4/6 (67%) achieved >80% reduction in UPCR; average 60% reduction across all dosed subjects.
No drug-related serious adverse events or treatment discontinuations; steroid tapered to <7.5 mg/day.
Top-line Type B data expected mid-2023; pending Metacrine acquisition also noted in filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.